Using a panel of non–small cell lung cancer (NSCLC) lines, we show here that MAP-ERK
kinase (MEK) and RAF inhibitors are selectively toxic for the KRAS-mutant genotype …

KRAS represents an excellent therapeutic target in lung cancer, the most commonly mutated
form of which can now be blocked using KRAS-G12C mutant-specific inhibitory trial drugs …

Adenocarcinoma of the lung, a leading cause of cancer death, frequently displays
mutational activation of the KRAS proto-oncogene but, unlike lung cancers expressing …

Oncogenic KRAS activation is responsible for the most common genetic subtype of lung
cancer. Although many of the major downstream signaling pathways that KRAS engages …

Purpose: KRAS-mutant lung cancers have been recalcitrant to treatments including those
targeting the MAPK pathway. Covalent inhibitors of KRAS p. G12C allele allow for direct and …

Oncogenic KRAS is found in more than 25% of lung adenocarcinomas, the major histologic
subtype of non–small cell lung cancer (NSCLC), and is an important target for drug …

Although several groups have demonstrated that concomitant use of MEK and
phosphoinositide 3-kinase (PI3K) inhibitors (MEKi/PI3Ki) can induce dramatic tumor …

K-RAS mutated (K-RAS mut) non-small cell lung cancer (NSCLC) cells are resistant to
EGFR targeting strategies. We investigated the impact of K-RAS activity irrespective of …

Lung adenocarcinomas harboring activating mutations in the epidermal growth factor
receptor (EGFR) represent a common molecular subset of non-small cell lung cancer …

KRAS is the most frequently mutated driver oncogene in human adenocarcinoma of the
lung. There are presently no clinically proven strategies for treatment of KRAS-driven lung …